Celcuity (CELC) vs Denali Therapeutics (DNLI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
Celcuity (CELC) has outperformed Denali Therapeutics (DNLI) over the past year, gaining 33.7% versus a gain of 28.6%. Over five years, CELC leads with a +261.4% price change compared with -57.9% for DNLI. Celcuity is the larger company by market cap ($3.22 billion vs $3.06 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CELC | DNLI |
|---|---|---|
| Share price | $65.78 | $19.16 |
| Market cap | $3.22B | $3.06B |
| 1-day change | -7.68% | -0.62% |
| YTD return | -34.05% | +16.05% |
| 1-year return | +33.66% | +28.59% |
| 5-year return | +261.43% | -57.95% |
| EPS (TTM) | $-4.17 | $-2.84 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $151.02 | $27.30 |
| 52-week low | $45.03 | $13.75 |
| Distance from 52-week high | -56.44% | -29.82% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +138.54% | +88.20% |
| Average volume | 1.19M | 1.61M |
| Shares outstanding | 48.93M | 159.85M |
| Employees | 155 | 503 |
| Sector | Health Care | Health Care |
| Industry | Medical Specialities | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Celcuity
CELC stock →Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's lead drug candidate includes Gedatolisib, which selectively targets various Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2 to treat patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) or HR+/HER2-, advanced or metastatic breast cancer (ABC), and patients with metastatic castration resistant prostate cancer (mCRPC).
Health Care · Medical Specialities · 155 employees
About Denali Therapeutics
DNLI stock →Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Syndrome A); and DNL310 Tividenofusp alfa, an enzyme replacement therapy program for MPS II (Hunter Syndrome).
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 503 employees
CELC vs DNLI FAQ
Which is bigger, Celcuity or Denali Therapeutics?
Celcuity (CELC) is larger, with a market capitalization of $3.22B compared with $3.06B for Denali Therapeutics (DNLI).
Which stock has performed better over the past year, CELC or DNLI?
CELC returned +33.66% over the past 12 months, compared with +28.59% for DNLI (price return, excluding dividends). Past performance does not predict future results.
Are Celcuity and Denali Therapeutics in the same industry?
Both are in the Health Care sector, but in different industries: Medical Specialities for Celcuity and Biotechnology: Biological Products (No Diagnostic Substances) for Denali Therapeutics.